Plant Advanced Technologies SA (ALPAT.PA)
EUR 11.7
(-2.5%)
EUR 11.7
(-2.5%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.35 Million EUR | -17.85% |
| 2022 | 5.3 Million EUR | 45.29% |
| 2021 | 3.65 Million EUR | 47.83% |
| 2020 | 2.46 Million EUR | 75.54% |
| 2019 | 1.4 Million EUR | -56.62% |
| 2018 | 3.24 Million EUR | 45.44% |
| 2017 | 2.22 Million EUR | 15.35% |
| 2016 | 1.93 Million EUR | -6.23% |
| 2015 | 2.06 Million EUR | -10.01% |
| 2014 | 2.29 Million EUR | 68.0% |
| 2013 | 1.36 Million EUR | 850.21% |
| 2012 | 143.47 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 FY | 4.35 Million EUR | -17.85% |
| 2023 Q4 | 4.35 Million EUR | 0.0% |
| 2023 Q2 | 4.52 Million EUR | 0.0% |
| 2022 FY | 5.3 Million EUR | 45.29% |
| 2022 Q2 | 4.67 Million EUR | 0.0% |
| 2022 Q4 | 5.3 Million EUR | 0.0% |
| 2021 Q4 | 3.65 Million EUR | 0.0% |
| 2021 FY | 3.65 Million EUR | 47.83% |
| 2021 Q2 | 3.33 Million EUR | 0.0% |
| 2020 Q2 | 2.34 Million EUR | 0.0% |
| 2020 FY | 2.46 Million EUR | 75.54% |
| 2020 Q4 | 4.03 Million EUR | 0.0% |
| 2019 Q2 | 3.62 Million EUR | 0.0% |
| 2019 FY | 1.4 Million EUR | -56.62% |
| 2019 Q4 | 1.4 Million EUR | 0.0% |
| 2018 Q2 | 3.65 Million EUR | 0.0% |
| 2018 FY | 3.24 Million EUR | 45.44% |
| 2018 Q4 | 3.24 Million EUR | 0.0% |
| 2017 Q2 | 2.23 Million EUR | 0.0% |
| 2017 FY | 2.22 Million EUR | 15.35% |
| 2017 Q4 | 2.24 Million EUR | 0.0% |
| 2016 Q2 | 2.54 Million EUR | 0.0% |
| 2016 FY | 1.93 Million EUR | -6.23% |
| 2016 Q4 | 1.93 Million EUR | 0.0% |
| 2015 FY | 2.06 Million EUR | -10.01% |
| 2015 Q4 | 2.06 Million EUR | 0.0% |
| 2015 Q2 | 1.89 Million EUR | 0.0% |
| 2014 Q4 | 2.29 Million EUR | 0.0% |
| 2014 Q2 | 1.36 Million EUR | 0.0% |
| 2014 FY | 2.29 Million EUR | 68.0% |
| 2013 FY | 1.36 Million EUR | 850.21% |
| 2013 Q4 | 1.36 Million EUR | 0.0% |
| 2012 FY | 143.47 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 710.155% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 102.217% |
| Adocia SA | 127 Thousand EUR | -3330.322% |
| Aelis Farma SA | -16.19 Million EUR | 126.905% |
| Biophytis S.A. | 2.7 Million EUR | -61.173% |
| Advicenne S.A. | 12.17 Million EUR | 64.218% |
| genOway Société anonyme | 2.97 Million EUR | -46.537% |
| IntegraGen SA | -709.74 Thousand EUR | 713.81% |
| Medesis Pharma S.A. | 1.15 Million EUR | -276.142% |
| Neovacs S.A. | -237.08 Thousand EUR | 1937.515% |
| NFL Biosciences SA | -2.27 Million EUR | 291.422% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 624.534% |
| Sensorion SA | 1.37 Million EUR | -216.096% |
| Theranexus Société Anonyme | 2.44 Million EUR | -78.242% |
| TME Pharma N.V. | -1.07 Million EUR | 503.754% |
| Valbiotis SA | -18.13 Million EUR | 124.017% |
| TheraVet SA | 12.78 Thousand EUR | -33975.158% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | -99.84% |
| argenx SE | -1.83 Billion EUR | 100.237% |
| BioSenic S.A. | 28.04 Million EUR | 84.465% |
| Celyad Oncology SA | -6.1 Million EUR | 171.395% |
| DBV Technologies S.A. | -114.95 Million USD | 103.79% |
| Galapagos NV | -157.2 Million EUR | 102.771% |
| Genfit S.A. | -7.61 Million EUR | 157.24% |
| GeNeuro SA | 5.91 Million EUR | 26.291% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 117.348% |
| Innate Pharma S.A. | -30.71 Million EUR | 114.185% |
| Inventiva S.A. | 10.48 Million EUR | 58.466% |
| MaaT Pharma SA | -10.2 Million EUR | 142.69% |
| MedinCell S.A. | 39.5 Million EUR | 88.971% |
| Nanobiotix S.A. | -24.71 Million EUR | 117.625% |
| Onward Medical N.V. | -12.89 Million EUR | 133.787% |
| Oryzon Genomics S.A. | 1.43 Million EUR | -204.58% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 83.942% |
| Oxurion NV | 10.71 Million EUR | 59.323% |
| Pharming Group N.V. | 99.4 Million EUR | 95.617% |
| Poxel S.A. | 44.55 Million EUR | 90.223% |
| GenSight Biologics S.A. | 16.29 Million EUR | 73.263% |
| Transgene SA | -14.4 Million EUR | 130.235% |
| Financière de Tubize SA | 78.62 Million EUR | 94.459% |
| UCB SA | 2.17 Billion EUR | 99.8% |
| Valneva SE | 82.73 Million EUR | 94.734% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 123.518% |